UK markets close in 2 hours 43 minutes
  • FTSE 100

    6,989.86
    -35.57 (-0.51%)
     
  • FTSE 250

    22,924.71
    -8.48 (-0.04%)
     
  • AIM

    1,233.61
    -0.07 (-0.01%)
     
  • GBP/EUR

    1.1696
    -0.0010 (-0.08%)
     
  • GBP/USD

    1.3819
    -0.0005 (-0.04%)
     
  • BTC-GBP

    27,687.98
    -477.15 (-1.69%)
     
  • CMC Crypto 200

    910.56
    -4.92 (-0.54%)
     
  • S&P 500

    4,422.30
    +10.51 (+0.24%)
     
  • DOW

    35,144.31
    +82.76 (+0.24%)
     
  • CRUDE OIL

    71.78
    -0.13 (-0.18%)
     
  • GOLD FUTURES

    1,804.10
    +4.90 (+0.27%)
     
  • NIKKEI 225

    27,970.22
    +136.93 (+0.49%)
     
  • HANG SENG

    25,086.43
    -1,105.89 (-4.22%)
     
  • DAX

    15,526.49
    -92.49 (-0.59%)
     
  • CAC 40

    6,544.80
    -33.80 (-0.51%)
     

SHAREHOLDER ALERT: Robbins LLP Announces that AcelRX Pharmaceuticals, Inc. (ACRX) is Being Sued for Misleading Shareholders

·2-min read

SAN DIEGO & HAYWARD, Calif., Jun 14, 2021--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a class action has been filed on behalf of all purchasers of AcelRx Therapeutics, Inc. (NASDAQ:ACRX) securities between March 17, 2020 and February 12, 2021, against the Company for remedies under the Securities Exchange Act of 1934. AcelRx is a pharmaceutical company that develops and commercializes therapies for the treatment of acute pain. The Company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-sever acute pain.

If you suffered a loss due to AcelRx Therapeutics, Inc.'s misconduct, click here.

AcelRx Therapeutics, Inc. (ACRX) Made Misstatements in Advertising for its Lead Drug Candidate DSUVIA

According to the complaint, during the relevant period, defendants made false and/or misleading statements and/or failed to disclose that: (i) AcelRx had deficient disclosure controls and procedures with respect to its marketing of DSUVIA; (ii) as a result, AcelRx had been making false or misleading claims and representations about the risks and efficacy of DSUVIA in certain advertisements and displays; (iii) this conduct subjected the Company to increased regulatory scrutiny and enforcement; and (iv) as a result, the Company's public statements were materially false and misleading.

On February 16, 2021, AcelRx disclosed that, on February 11, 2021, the Company received a warning letter from the FDA concerning promotional claims for DSUVIA. Specifically, having "reviewed an 'SDS Banner Ad' (banner) (PM-US-DSV-0018) and a tabletop display (PM-US-DSV-0049) (display)," the FDA concluded that "[t]he promotional communications, the banner and display, make false or misleading claims and representations about the risks and efficacy of DSUVIA," and "[t]hus … misbrand DSUVIA within the meaning of the Federal Food, Drug and Cosmetic Act (FD&C Act) and make its distribution violative." The earning letter "request[ed] that AcelRx cease any violations of the FD&C Act" and "submit a written response to th[e] letter within 15 days from the date of receipt."

On this news, AcelRx's stock price fell $0.21 per share, or 8.37%, to close at $2.30 per share on February 16, 2021. The stock now trades at around $1.50.

If you purchased shares of AcelRx Therapeutics, Inc. (ACRX) between March 17, 2020 and February 12, 2021, you have until August 9, 2021, to ask the court to appoint you lead plaintiff for the class.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against AcelRx Therapeutics, Inc. settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210614005610/en/

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting